NeuroStar TMS Therapy System: Utilization and Outcomes
1 other identifier
observational
307
1 country
44
Brief Summary
The major objective of this observational study is to describe clinical outcomes of patients receiving treatment with the NeuroStar TMS Therapy system in routine clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2010
Typical duration for all trials
44 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2010
CompletedFirst Submitted
Initial submission to the registry
April 23, 2010
CompletedFirst Posted
Study publicly available on registry
May 3, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2012
CompletedNovember 13, 2015
November 1, 2015
2.5 years
April 23, 2010
November 11, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Total Score on the Patient Health Questionnaire 9-Item (PHQ-9)
The primary outcome measure will reported as the change from baseline through 6 weeks for the total score on the PHQ-9.
Baseline and 6 weeks
Secondary Outcomes (5)
Total score for the Clinical Global Impressions-Severity (CGI-S)
Baseline, 6 weeks and 12 Months
Total score for the Inventory of Depressive Symptoms-Self Report (IDS-SR)
Baseline, 6 weeks and 12 Months
Total Score for the EuroQol Questionnaire (EQ-5D)
Baseline, 6 weeks, and 12 Months.
Health Resource Utilization Questionnaire (HRU)
Baseline, 6 weeks, and 12 Months
Short Form 36-Item Questionnaire(SF-36) Individual Factor Scores and General Medical and Mental Health Composite Scores
Baseline, 6 weeks, and 12 Months.
Eligibility Criteria
Clinical practice locations providing clinical treatment with the NeuroStar TMS Therapy System.
You may qualify if:
- Major Depressive Disorder
You may not qualify if:
- Contraindications to treatment with TMS
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Neuroneticslead
Study Sites (44)
Lee Ann Kelley, M.D., PC
Phoenix, Arizona, 85032, United States
Bay Psychiatric Associates
Berkeley, California, 94704, United States
TMS Center of Beverly Hills
Beverly Hills, California, 90210, United States
Clinical Training & Research Institute
Burlingame, California, 94010, United States
Sacramento TMS
El Dorado Hills, California, 95762, United States
Martha Koo, MD
Hermosa Beach, California, 90254, United States
Orange County TMS Center
Laguna Hills, California, 92653, United States
Depression Research Center and Clinic-Semel Institute for Neuroscience & Human Behavior at UCLA
Los Angeles, California, 90024, United States
Kevin Kinback, MD
Mission Viejo, California, 92691, United States
Todd Hutton, MD & Associates
Pasadena, California, 91101, United States
The Botkiss Center for TMS Therapy
San Diego, California, 92130, United States
Stanford Hospital and Clinics
Stanford, California, 94305, United States
Arjun Reyes, MD
Woodland Hills, California, 91364, United States
Hartford Hospital
Hartford, Connecticut, 06102, United States
Comprehensive Psychiatric Care
Norwich, Connecticut, 06360, United States
Christiana Care Health Services
Wilmington, Delaware, 19801, United States
Health Sciences America, LLC
Boca Raton, Florida, 33432, United States
Curtis Cassidy, MD
Lakeland, Florida, 33803, United States
Brian Teliho, MD
Atlanta, Georgia, 30305, United States
Carl M. Wahlstrom, Jr. MD Limited
Chicago, Illinois, 60601, United States
Northwestern Medical Faculty Foundation
Chicago, Illinois, 60611, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
Brain Stimulation Chicago North Shore
Northbrook, Illinois, 60062, United States
Behavioral Health Care Associates
Schaumburg, Illinois, 60194, United States
University Psychiatric Foundation
Louisville, Kentucky, 40202, United States
Integrative Psychiatry
Louisville, Kentucky, 40222, United States
Spectrum Behavioral Health
Annapolis, Maryland, 21401, United States
Sheppard Pratt Health System
Baltimore, Maryland, 21285, United States
Anthony Drobnick, MD
Saint Michaels, Maryland, 21663, United States
Newton-Wellesley Psychiatry
Newton, Massachusetts, 02462, United States
Central Psychiatry
Las Vegas, Nevada, 89146, United States
TMS Center of New England
Portsmouth, New Hampshire, 03801, United States
Santa Fe TMS Therapy Center
Santa Fe, New Mexico, 87501, United States
Dent Neurosciences Research Center, Inc.
Amherst, New York, 14226, United States
The TMS Institute of Pennsylvania-Advanced Neuropsychiatric Solutions
West Chester, Pennsylvania, 19382, United States
Butler Hospital
Providence, Rhode Island, 02906, United States
W. Scott West, M.D.
Nashville, Tennessee, 37215, United States
Texas Neuropsychiatric Institute
Amarillo, Texas, 79106, United States
Texas TMS Center at Senior Adults Specialty Healthcare (SASH)
Austin, Texas, 78757, United States
Houston TMS
Houston, Texas, 77024, United States
Agape Mind Services/The Costello Clinic
Lewisville, Texas, 75077, United States
Serenity Center for Depression, P.A.
Sugar Land, Texas, 77479, United States
University Neuropsychiatric Institute
Salt Lake City, Utah, 84108, United States
Center for Anxiety and Depression
Mercer Island, Washington, 98040, United States
Related Publications (2)
Dunner DL, Aaronson ST, Sackeim HA, Janicak PG, Carpenter LL, Boyadjis T, Brock DG, Bonneh-Barkay D, Cook IA, Lanocha K, Solvason HB, Demitrack MA. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. J Clin Psychiatry. 2014 Dec;75(12):1394-401. doi: 10.4088/JCP.13m08977.
PMID: 25271871DERIVEDJanicak PG, Dunner DL, Aaronson ST, Carpenter LL, Boyadjis TA, Brock DG, Cook IA, Lanocha K, Solvason HB, Bonneh-Barkay D, Demitrack MA. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. CNS Spectr. 2013 Dec;18(6):322-32. doi: 10.1017/S1092852913000357. Epub 2013 Jul 30.
PMID: 23895940DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Mark Demitrack, MD
Neuronetics, Inc.
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 23, 2010
First Posted
May 3, 2010
Study Start
March 1, 2010
Primary Completion
September 1, 2012
Study Completion
September 1, 2012
Last Updated
November 13, 2015
Record last verified: 2015-11